Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations
Canopy Growth expands its Australian medical cannabis offerings with new pastille, vape, oil, and softgel products.Summary
Canopy Growth Corporation has announced a significant expansion of its medical cannabis portfolio in Australia, introducing new product formats and formulations across its brands. The company is launching its first pastille and all-in-one vape formats in the market, alongside expanded oil and softgel offerings that include new cannabinoid profiles like CBG and CBN. New flower SKUs are also added to its value range. This expansion is part of Canopy Growth's international medical strategy to meet growing demand for product variety. CEO Luc Mongeau highlighted the strength of the global supply chain in enabling this growth. The company aims to provide clinicians and patients with more tailored treatment options, leveraging insights from its Canadian network.
(Source：The Kingston Whig-Standard)
